National Research Corporation (NRC), a prominent player in the Health Information Services industry, offers insights and analytics to healthcare organizations across the United States. With a market capitalization of $405.8 million, NRC stands out in the healthcare sector, primarily due to its impressive Return on Equity (ROE) of 51.24%. This figure is a strong indicator of the company’s efficiency in generating profits from its shareholders’ equity, suggesting robust management performance.
The current stock price of NRC is $17.84, reflecting a slight price change of 0.80 (0.05%). The 52-week range, spanning from $10.13 to $22.48, highlights the stock’s volatility and potential opportunities for investors who can time their entry and exits wisely. Despite the lack of available valuation metrics like the P/E ratio, price/book, and price/sales, NRC’s positive cash flow of $16.65 million is a testament to its capability to generate liquidity and sustain operations.
Interestingly, NRC’s revenue growth has contracted by 4.60%, which may raise concerns about the company’s ability to expand its market share or enhance its service offerings. However, it’s crucial to consider the company’s strategic focus on integrating technology with healthcare solutions. NRC’s offerings, such as the AI engine Huey, emphasize innovation and a forward-thinking approach that could potentially offset the current revenue decline.
The dividend yield of 3.14% is appealing for income-focused investors, but it’s also essential to note the high payout ratio of 104.00%. This suggests that NRC is distributing more in dividends than its earnings, which might not be sustainable long-term without growth in earnings or adjustments in dividend policy.
As for analyst ratings, the absence of buy, hold, or sell ratings, along with the lack of a defined target price range, indicates that analysts may be adopting a wait-and-see approach. The high RSI (14) of 77.23 suggests that the stock is overbought, which might prompt a cautious stance among investors seeking to enter at a more favorable price point.
From a technical perspective, NRC’s stock is trading above both its 50-day and 200-day moving averages, at $15.55 and $15.75 respectively. This upward trend is generally positive, suggesting that the stock is in a bullish phase. However, the MACD and Signal Line figures, at 0.30 and 0.35 respectively, imply a need for careful monitoring as these indicators hint at potential shifts in momentum.
Investors interested in NRC should consider the company’s innovative solutions and their applicability in the evolving healthcare landscape. With its headquarters in Lincoln, Nebraska, and a foundation dating back to 1981, National Research Corporation has a long-standing presence and a reputation for delivering value through data-driven insights. As the healthcare industry continues to adapt to technological advancements, NRC’s focus on experience management and community insights positions it as a potential candidate for growth in the long term, despite current challenges in revenue expansion.
